Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020
April 27, 2020 at 04:02 am
Share
Jiangsu Sihuan Bioengineering Co. Ltd. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was CNY 157.012 million compared to CNY 67.767 million a year ago. Operating income was CNY 10.014 million compared to operating loss of CNY 13.983 million a year ago. Net income was CNY 10.309 million compared to net loss of CNY 12.792 million a year ago. Basic earnings per share from continuing operations was CNY 0.01 compared to basic loss per share from continuing operations of CNY 0.0124 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
